90 results
8-K
EX-10.1
CELU
Celularity Inc - Ordinary Shares
17 Jan 24
Entry into a Material Definitive Agreement
4:14pm
U.S. Governmental Authority acting in its capacity as a member of CFIUS or directly involved in CFIUS’s assessment, review or investigation … (or an agency or subdivision thereof) or other entity of any kind.
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without
8-K
EX-10.1
CELU
Celularity Inc - Ordinary Shares
19 May 23
Entry into a Material Definitive Agreement
4:26pm
, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition) pending … or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective
8-K
EX-10.3
CELU
Celularity Inc - Ordinary Shares
15 Mar 24
Entry into a Material Definitive Agreement
5:01pm
, joint or several (collectively, “Claims”) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation … withheld. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person.
(b
8-K
EX-10.1
CELU
Celularity Inc - Ordinary Shares
8 Jan 21
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
7:03am
as disclosed in the SEC Reports, as of the date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of GX … that a possibility of total loss exists.
(h) In making its decision to purchase the Shares, the Investor has relied solely upon independent investigation made
8-K
EX-10.1
CELU
Celularity Inc - Ordinary Shares
28 Jul 23
Celularity Inc. Announces $3 Million Registered Direct Offering
4:27pm
.
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding … or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective
425
EX-10.1
uo3isz 585spi1b
8 Jan 21
Business combination disclosure
7:02am
8-K
EX-10.1
s51d3
6 Apr 23
Celularity Inc. Announces $6 Million Registered Direct Offering
8:58pm
8-K
EX-10.1
4uixtngc
20 May 22
Celularity Inc. Announces $30 Million Private Placement
4:06pm
S-1
EX-10.5
2urxgtctqgeonrthw0q
26 Apr 19
IPO registration
4:23pm
DRS
EX-10.5
qgn69mf0h5b tp
5 Nov 18
Draft registration statement
12:00am
CORRESP
zjb4159murmlmlsp
4 Jun 21
Correspondence with SEC
12:00am
425
EX-2.1
mcvytupgzea ur7l
8 Jan 21
Business combination disclosure
7:02am
8-K
EX-2.1
q5iua pkgqm6gx9q
8 Jan 21
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
7:03am
S-4/A
EX-10.23
5ampn4lv5cv1ev
29 Mar 21
Registration of securities issued in business combination transactions (amended)
7:30am
S-1/A
EX-14
9lr9m99u gz
13 May 19
IPO registration (amended)
4:55pm
8-K
EX-10.3
kujg slh1pr9zdq0u2
28 Jul 23
Celularity Inc. Announces $3 Million Registered Direct Offering
4:27pm
8-K
EX-10.3
9oqz5hr
6 Apr 23
Celularity Inc. Announces $6 Million Registered Direct Offering
8:58pm
8-K
EX-10.4
40j29p bys7
20 May 22
Celularity Inc. Announces $30 Million Private Placement
4:06pm
S-1/A
EX-10.4
1b78s8wa
13 May 19
IPO registration (amended)
4:55pm